Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 316 to 330 of 1243 results for public health guidance

  1. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]

    Awaiting development Reference number: GID-TA11358 Expected publication date: TBC

  2. WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]

    Awaiting development Reference number: GID-TA11305 Expected publication date: TBC

  3. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]

    Awaiting development Reference number: GID-TA11271 Expected publication date: TBC

  4. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]

    Awaiting development Reference number: GID-TA11283 Expected publication date: TBC

  5. Sibeprenlimab for treating IgA nephropathy [ID6604]

    Awaiting development Reference number: GID-TA11668 Expected publication date: TBC

  6. Gantenerumab for treating early Alzheimer's disease [TSID10668]

    Awaiting development Reference number: GID-TA11072 Expected publication date: TBC

  7. Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763]

    Awaiting development Reference number: GID-TA11048 Expected publication date: TBC

  8. Sabizabulin for treating COVID-19 [TSID11814]

    Awaiting development Reference number: GID-TA11226 Expected publication date: TBC

  9. Antimicrobial stewardship (QS121)

    This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.

  10. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  11. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  12. Surgical site infection (QS49)

    This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.

  13. Consultancy service

    Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country

  14. Social care

    Home Implementing NICE guidance...

  15. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.